Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On November7, 2017, we issued a press release announcing our results for the quarter ended September30, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
This information and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Financial Statements and Exhibits. |
| (d) | The following exhibit is included in this report: |
|
Exhibit No. |
Description |
| 99.1 | Press release dated November7, 2017 |
INFINITY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d492748dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results – Late-Breaking Abstract Reporting Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Study of IPI-549 in Patients with Advanced Solid Tumors to be Presented During Oral New Agents Session at SITC – – Company to Host Investor and Analyst Reception Friday,…To view the full exhibit click here
About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
